72 results about "Clinical correlation" patented technology

The invention describes for the first time the preclinical / cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis. VIP and PACAP are synthesised in different areas of the central nervous system, e.g. in specific cerebral areas such as the hippocampus and the cortex, as well as in the peripheral ganglia. VIP is also released by immune cells.

A method and system for assessing alarm events generated in a physiological monitoring system is described. The method identifies one or more qualitative measures associated with the generation of the alarm event. The one or more qualitative measures can include a calculated trajectory of the monitored physiological parameter, the calculated time between alarm events and the duration of the current alarm event. Based upon the qualitative measures, the method calculates a clinical relevancy score for the alarm event. The alarm event, each of the qualitative measures and the clinical relevancy score are presented on a display panel. The method and system can generate an urgent alarm based on the calculated relevancy score. The system includes a processor that calculates the clinical relevancy score based on qualitative measures and algorithms entered into the processor.

The invention relates to the identification and use of gene expression profiles, or patterns, with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. It is to be understood and will be appreciated that the same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. Classifying may include stratifying the tumor (and thus stratifying a subject having the tumor), e.g., for a clinical trial. The methods may further comprise selecting a treatment based on the classifying step. The gene expression profiles may also aid in the early identification of patients who may be failing a therapeutic protocol with a gamma secretase inhibitor and thus provide the basis for early intervention.